Prime Medicine (PRME) Non-Current Assets (2021 - 2026)

Prime Medicine has reported Non-Current Assets for 6 years, with the latest figure at $156.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 4.6% year-over-year to $156.8 million; the trailing twelve-month figure through Mar 2026 stood at $629.6 million (up 47.92% YoY), and the FY2025 full-year result was $161.4 million, up 88.55% from the prior year.
• Non-Current Assets for Q1 2026 stood at $156.8 million, down from $161.4 million in the prior quarter.
• The five-year high for Non-Current Assets was $164.4 million in Q1 2025, with the low at $50.9 million in Q4 2023.
• Historically, Non-Current Assets has averaged $100.7 million across 5 years, with a median of $86.7 million in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Assets soared 103.65% — and 2023, when it fell 20.13%.
• Prime Medicine's Non-Current Assets stood at $63.7 million in 2022, then declined by 20.13% to $50.9 million in 2023, then jumped by 68.3% to $85.6 million in 2024, then soared by 88.55% to $161.4 million in 2025, then retreated by 2.85% to $156.8 million in 2026.
• The last three Non-Current Assets figures came in at $156.8 million (Q1 2026), $161.4 million (Q4 2025), and $153.6 million (Q3 2025), per Business Quant data.